|
시장보고서
상품코드
2050699
허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 유형별, 용도별, 유통 채널별, 지불 주체별, 투여 경로별, 치료 단계별, 환자층별, 지역별Herceptin Biologic and Biosimilar Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장은 2026년에 34억 9,000만 달러로 추계되고 있으며, 2033년까지 51억 9,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 34억 9,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 5.80% | 2033년 시장 규모 예측 : | 51억 9,000만 달러 |
허셉틴(Herceptin) 바이오의약품 및 바이오시밀러 시장은 HER2 양성 유방암 유병률 증가와 표적치료제에 대한 수요 증가를 배경으로 최근 수년간 괄목할 만한 성장세를 보이고 있습니다. 허셉틴(성분명: 트라스투주맙)은 유방암의 약 20-30%에서 과발현되는 HER2 단백질을 특이적으로 표적하는 모노클로널 항체입니다.
이 약은 HER2 양성 유방암 치료 환경에 혁명을 일으켜 환자의 예후와 생존율을 개선했습니다. HER2 양성 전이성 위암 치료 등 허셉틴의 적응증 확대로 시장 성장이 더욱 가속화되고 있습니다. 또한 바이오시밀러 개발 및 다른 치료제와 병용하는 허셉틴의 채택 확대는 시장 성장을 위한 새로운 길을 열어주고 있습니다. 이 보고서는 허셉틴 바이오의약품 및 바이오시밀러 시장에 대한 상세한 분석을 통해 주요 시장 동인, 제약, 기회 및 미래 전망을 밝힙니다.
시장 역학
허셉틴 바이오의약품 및 바이오시밀러 시장은 HER2 양성 유방암 발생률 증가, 표적치료제에 대한 인식 증가, 맞춤의료에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 또한 HER2 발현을 측정하는 동반 진단 검사의 개발은 허셉틴 치료로 가장 큰 혜택을 받을 가능성이 높은 환자를 식별할 수 있게 하여 시장 성장에 기여하고 있습니다. 그러나 허셉틴 치료의 높은 비용이 시장 성장을 저해하고 있으며, 특정 지역에서는 치료 접근성이 제한될 수 있습니다. 또한 바이오시밀러의 등장과 일부 국가에서의 허셉틴 특허 만료는 오리지널 의약품의 시장 점유율에 영향을 미칠 수 있습니다. 이러한 도전과제가 있는 반면, 시장에는 다른 HER2 양성 암에서의 허셉틴 적응증 확대, 새로운 병용요법 개발, 신흥 국가에서의 허셉틴 채택 확대 등 큰 성장 기회가 존재합니다. 또한 허셉틴의 효능과 안전성 향상을 위한 지속적인 연구개발 활동이 향후 수년간 시장 성장을 촉진할 것으로 예상됩니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 허셉틴 생물제제 및 바이오시밀러 시장의 주요 기업에 대해 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략 등의 매개 변수를 기반으로 프로파일을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 허셉틴 바이오로직스 및 바이오시밀러 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 허셉틴 생물제제 및 바이오시밀러 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 쉽게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 유형별, 2021-2033년
제5장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 용도별, 2021-2033년
제6장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 유통 채널별, 2021-2033년
제7장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 지불 주체별, 2021-2033년
제8장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 투여 경로별, 2021-2033년
제9장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 치료 라인별, 2021-2033년
제10장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 환자 속성별, 2021-2033년
제11장 허셉틴(Herceptin) 생물제제 및 바이오시밀러 시장 : 지역별, 2021-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
KSA 26.06.10Herceptin Biologic and Biosimilar Market is estimated to be valued at USD 3.49 Bn in 2026 and is expected to reach USD 5.19 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.49 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.80% | 2033 Value Projection: | USD 5.19 Bn |
Herceptin Biologic and Biosimilar Market has witnessed significant growth in recent years, driven by the increasing prevalence of HER2-positive breast cancer and the rising demand for targeted therapies. Herceptin, also known as trastuzumab, is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed in approximately 20-30% of breast cancers.
The drug has revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and survival rates. The market's growth is further fueled by the expanding indications of Herceptin, including its use in the treatment of HER2-positive metastatic gastric cancer. Moreover, the development of biosimilars and the increasing adoption of Herceptin in combination with other therapies have opened up new avenues for market growth. This report provides an in-depth analysis of the Herceptin Biologic and Biosimilar Market, highlighting its key drivers, restraints, opportunities, and future prospects.
Market Dynamics
The Herceptin Biologic and Biosimilar Market is driven by several factors, including the rising incidence of HER2-positive breast cancer, increasing awareness about targeted therapies, and the growing demand for personalized medicine. The development of companion diagnostic tests for HER2 expression has also contributed to the market's growth by enabling the identification of patients who are most likely to benefit from Herceptin treatment. However, the market growth is restrained by the high cost of Herceptin therapy, which may limit its accessibility in certain regions. Additionally, the emergence of biosimilars and the expiration of patents for Herceptin in some countries may impact the market share of the original drug. Despite these challenges, the market presents significant opportunities for growth, such as the expanding indications of Herceptin in other HER2-positive cancers, the development of novel drug combinations, and the increasing adoption of Herceptin in emerging economies. Furthermore, the ongoing research and development activities aimed at improving the efficacy and safety of Herceptin are expected to drive market growth in the coming years.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Herceptin Biologic and Biosimilar Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Genentech (Roche), Amgen, Pfizer, Merck & Co., AbbVie, Celgene, Bristol-Myers Squibb, AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, and EMD Serono
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The Herceptin Biologic and Biosimilar Marketreport caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Herceptin Biologic and Biosimilar Market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Biologic
- Biosimilars
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Breast Cancer Treatment
- Gastric Cancer Treatment
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Payer Type Insights (Revenue, USD Bn, 2021 - 2033)
- Public
- Private
- Administration Route Insights (Revenue, USD Bn, 2021 - 2033)
- Intravenous
- Subcutaneous
- Treatment Line Insights (Revenue, USD Bn, 2021 - 2033)
- First-line Treatment
- Second-line Treatment
- Third-line Treatment
- Patient Demographics Insights (Revenue, USD Bn, 2021 - 2033)
- Age Groups
- Pediatric
- Adult
- Geriatric
- Gender
- Male
- Female
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Genentech (Roche)
- Amgen
- Pfizer
- Merck & Co.
- AbbVie
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- GSK (GlaxoSmithKline)
- Novartis
- Sanofi
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- EMD Serono
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Herceptin Biologic and Biosimilar Market, By Type
- Herceptin Biologic and Biosimilar Market, By Application
- Herceptin Biologic and Biosimilar Market, By Distribution Channel
- Herceptin Biologic and Biosimilar Market, By Payer Type
- Herceptin Biologic and Biosimilar Market, By Administration Route
- Herceptin Biologic and Biosimilar Market, By Treatment Line
- Herceptin Biologic and Biosimilar Market, By Patient Demographics
- Herceptin Biologic and Biosimilar Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Herceptin Biologic and Biosimilar Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Biologic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Herceptin Biologic and Biosimilar Market, By Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Breast Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gastric Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Herceptin Biologic and Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Herceptin Biologic and Biosimilar Market, By Payer Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Herceptin Biologic and Biosimilar Market, By Administration Route, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Herceptin Biologic and Biosimilar Market, By Treatment Line, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- First-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Second-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Third-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Herceptin Biologic and Biosimilar Market, By Patient Demographics, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric
- Adult
- Geriatric
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Male
- Female
11. Herceptin Biologic and Biosimilar Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Genentech (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EMD Serono
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
